文献速递免疫规划

BNT162b2同源与CoronaVac-BNT162b2异源加强接种后S1-RBD-IgG和S1-RBD-IgA水平相当且持久:马来西亚22个月前瞻性研究

Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
PubMed 文献 · Vaccine · 2024-10-28

该前瞻性队列研究在马来西亚纳入146名受试者,比较三剂BNT162b2同源方案(PPP)与两剂CoronaVac后BNT162b2加强(SSP)的长期体液免疫应答。结果显示BNT162b2加强针显著提高血清抗S1-RBD-IgG和-IgA水平并维持至接种后26至52周,两组加强后水平相当;Omicron突破感染未导致上述抗体升高,多剂接种后未见抗S1-RBD-IgM显著诱导。

要点

  • 两剂基础免疫中BNT162b2优于CoronaVac。
  • BNT162b2加强针显著提高抗S1-RBD-IgG和-IgA并维持26至52周。
  • PPP与SSP组加强后抗S1-RBD-IgG和-IgA水平相当。

核心结论

  • PPP与SSP组对SARS-CoV-2的长期体液免疫应答相当,在本队列中显示mRNA加强针的优势。

研究设计与样本

  • 前瞻性队列研究,纳入146名在马来西亚接种COVID-19疫苗的个体,分为三剂BNT162b2同源方案(PPP)组和两剂CoronaVac后BNT162b2加强(SSP)组。

主要发现

  • 两剂基础免疫系列中BNT162b2优于CoronaVac。
  • BNT162b2加强针显著提高血清抗S1-RBD-IgG和-IgA水平,并维持接种后26至52周的升高,无论疫苗方案如何。
  • BNT162b2加强后两组抗S1-RBD-IgG和-IgA水平相当。
  • 突破感染(尤其Omicron变异株出现后)未导致抗S1-RBD-IgG和-IgA水平升高。
  • 多剂疫苗接种后未观察到抗S1-RBD-IgM的显著诱导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This prospective cohort study examines the long-term humoral immune responses post-COVID-19 vaccination in 146 individuals who received either a homologous three-dose BNT162b2 vaccine regimen (PPP) or two primary doses of CoronaVac followed by BNT162b2 booster (SSP) in Malaysia. The study focuses on serum anti-S1-RBD-IgG, -IgA, and -IgM, using the ELISA method. The results show that BNT162b2 outperformed CoronaVac in the two dose primary vaccination series. BNT162b2 booster dose significantly raised serum anti-S1-RBD-IgG and -IgA levels, sustaining this increase from 26 to 52 weeks after administration, regardless of the vaccine regimen. This leads to equivalent levels of anti-S1-RBD-IgG and -IgA after boosting with BNT162b2 in both groups. Breakthrough infections, particularly with the emergence of the Omicron variant, did not result in increased anti-S1-RBD-IgG and -IgA levels. No significant induction of anti-S1-RBD-IgM was observed following multiple vaccine doses. The long-term investigation revealed that PPP and SSP groups had comparable humoral immune responses to SARS-CoV-2, highlighting the advantage of mRNA booster dose in our cohort.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mohd Hisham AA, Mat Yassim AS, Suppian R, et al. Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia. Vaccine. 2024. PMID: 39490114. doi:10.1016/j.vaccine.2024.126471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。